CHD9 polyclonal antibody, anti-human, mouse

Background:
Acts as a transcriptional coactivator for PPARA and possibly other nuclear receptors. Proposed to be a ATP-dependent chromatin remodeling protein. Has DNA-dependent ATPase activity and binds to A/T-rich DNA. Associates with A/T-rich regulatory regions in promoters of genes that participate in the differentiation of progenitors during osteogenesis.,PTM:Phosphorylated on serine and tyrosine residues.,sequence Wrong choice of frame.,Belongs to the SNF2/RAD54 helicase family.,Contains 1 helicase ATP-binding domain.,Contains 1 helicase C-terminal domain.,Contains 2 chromo domains.,subunit:Interacts with PPARA. Probably interacts with ESR1 and NR1I3.,tissue specificity:Widely expressed at low levels. In bone marrow, expression is restricted to osteoprogenitor cells adjacent to mature osteoblasts.,

Research Area: Epigenetics and nuclear signaling

Synonyms: Chromodomain-helicase-DNA-binding protein 9 , CHD-9, EC 3.6.4.12, ATP-dependent helicase CHD9, Chromatin-related mesenchymal modulator, CReMM, Chromatin-remodeling factor CHROM1, Kismet homolog 2

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage:
-20°C for 1 year